SCHEMBL5157529

SCHEMBL5157529

C=CC(=O)NCCCCCC[N+](C)(C)C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZDHHC20 Q5W0Z9 1/20 0.65
ZDHHC2 Q9UIJ5 1/20 0.65
TSHR P16473 2/20 0.43
MAPK1 P28482 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TGM2 P21980 2/20 0.43
KMT2A Q03164 5/20 0.42
ATM Q13315 1/20 0.42
MEN1 O00255 4/20 0.41
APEX1 P27695 3/20 0.41
KDM4E B2RXH2 3/20 0.41
ACHE P22303 3/20 0.41
NFKB1 P19838 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PMP22 Q01453 2/20 0.41
LMNA P02545 2/20 0.41
HSD17B10 Q99714 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL31301132 0.98 ZDHHC20 (0.62) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
Hydrochloric Acid SCHEMBL20528844 0.98 ZDHHC20 (0.62) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
Hydrochloric Acid SCHEMBL31301131 0.98 ZDHHC20 (0.62) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
Iodide SCHEMBL31301133 0.98 ZDHHC20 (0.62) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
SCHEMBL18331491 0.98 ZDHHC20 (0.61) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
Hydrochloric Acid SCHEMBL3120286 0.96 ZDHHC20 (0.59) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
Bromide SCHEMBL6116865 0.96 ZDHHC20 (0.59) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
SCHEMBL192702 0.92 ZDHHC20 (0.58) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
Iodide SCHEMBL17105877 0.91 ZDHHC20 (0.56) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1
Bromide SCHEMBL475865 0.91 ZDHHC20 (0.56) ZDHHC20ZDHHC2TSHRMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014999-B1 CATIONIC POLYMERS AS TOXIN-BINDING AGENTS GENZYME CORP (US) 2004-12-08 EP claimed
EP-1014999-A1 CATIONIC POLYMERS AS TOXIN-BINDING AGENTS GELTEX PHARMACEUTICALS, INC. (US) 2000-07-05 EP claimed
EP-0915705-A1 IONIC POLYMERS AS ANTI-INFECTIVE AGENTS GELTEX PHARMACEUTICALS, INC. (US) 1999-05-19 EP claimed
WO-1999015186-A1 CATIONIC POLYMERS AS TOXIN-BINDING AGENTS GELTEX PHARMACEUTICALS, INC. (US) 1999-04-01 WO claimed
WO-1997049413-A1 IONIC POLYMERS AS ANTI-INFECTIVE AGENTS GELTEX PHARMACEUTICALS, INC. (US) 1997-12-31 WO claimed
EP-3274069-B1 METHOD OF PURIFYING A BIOLOGICAL COMPOSITION AND ARTICLE THEREFOR 3M INNOVATIVE PROPERTIES CO (US) 2020-08-19 EP disclosed
US-10562997-B2 Method of purifying a biological composition and article therefor 3M INNOVATIVE PROPERTIES COMPANY (US) 2020-02-18 US disclosed
US-20180066095-A1 Method of Purifying a Biological Composition and Article Therefor SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2018-03-08 US disclosed
EP-3274069-A1 METHOD OF PURIFYING A BIOLOGICAL COMPOSITION AND ARTICLE THEREFOR 3M Innovative Properties Company (US) 2018-01-31 EP disclosed
US-20160367980-A1 ION-EXCHANGE POLYMER AND PRODUCTION METHOD THEREFOR, ELECTROLYTE MEMBRANE AND PRODUCTION METHOD THEREFOR, AND COMPOSITION FOR PRODUCING ION-EXCHANGE POLYMER FUJIFILM CORPORATION (JP) 2016-12-22 US disclosed
WO-2016153915-A1 METHOD OF PURIFYING A BIOLOGICAL COMPOSITION AND ARTICLE THEREFOR 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-09-29 WO disclosed
EP-0915705-B1 IONIC POLYMERS AS ANTI-INFECTIVE AGENTS GENZYME CORP (US) 2007-01-10 EP disclosed
US-20010053794-A1 Ionic polymers as anti-infective agents GENZYME CORPORATION 2001-12-20 US disclosed
US-6290947-B1 IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. GELTEX PHARMACEUTICALS, INC. 2001-09-18 US disclosed
EP-1014999-A1 CATIONIC POLYMERS AS TOXIN-BINDING AGENTS GELTEX PHARMACEUTICALS, INC. (US) 2000-07-05 EP disclosed
US-6034129-A GASTROINTESTINAL DISORDERS GELTEX PHARMACEUTICALS, INC. (US) 2000-03-07 US disclosed
US-6007803-A ADMINISTERING TO MAMMAL A CATIONIC POLYMER TO INHIBIT PATHOGENIC TOXINS GELTEX PHARMACEUTICALS, INC. (US) 1999-12-28 US disclosed
EP-0915705-A1 IONIC POLYMERS AS ANTI-INFECTIVE AGENTS GELTEX PHARMACEUTICALS, INC. (US) 1999-05-19 EP disclosed
WO-1999015186-A1 CATIONIC POLYMERS AS TOXIN-BINDING AGENTS GELTEX PHARMACEUTICALS, INC. (US) 1999-04-01 WO disclosed
WO-1997049413-A1 IONIC POLYMERS AS ANTI-INFECTIVE AGENTS GELTEX PHARMACEUTICALS, INC. (US) 1997-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053794-A1 Ionic polymers as anti-infective agents PAM, ARG1, PIGS ZDHHC20 2918/4885ZDHHC2 3988/4885TSHR 4262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.